Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...

Subcutaneous pembrolizumab matched IV Keytruda in key pharmacokinetic metrics in a Phase 3 NSCLC trial. Safety and efficacy ...

US pharma giant Merck & Co (NYSE: MRK) today announced positive top-line results from the pivotal Phase III MK-3475A-D77 ...

Merck (MRK) stock gains as its subcutaneously delivered pembrolizumab meets key goals in Phase 3 trial against intravenous ...

Merck (MRK) announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of ...

Keytruda is an immunotherapy and works by stimulating the immune system to attack tumors. The Phase 3 trial evaluated subcutaneous administration of pembrolizumab, which is usually administered ...

Merck (NYSE:MRK) marked a major milestone in its bid to introduce a new formulation for its famous cancer therapy ...

Neoadjuvant immunotherapy offers a survival benefit in specific subtypes of patients but seems to offer no benefit in the ...

Among 64 patients who received immune checkpoint inhibitors, 78% had downstaging of their liver tumor to within Milan ...

Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a subcutaneous ...

SALMONELLA is normally associated with violent food poisoning. But now scientists believe the horror bug could be manipulated ...

Through a first-of-its-kind report, the Canadian Mental Health Association (CMHA) is providing an in-depth look at the mental health system in Canada?with all its cracks and failings?and how people ...